Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune...

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Metastatic cancers often develop resistance to immunotherapy, necessitating new treatment approaches.
• DNA damage response (DDR) proteins are established therapeutic targets, with specific inhibitors (DDRi) now in clinical trials.
• Emerging preclinical data suggest DDRi may enhance anti-tumor immunity, potentially augmenting immunotherapy efficacy.

Purpose of the Study:

• To investigate the mechanisms by which DDR inhibitors might stimulate anti-tumor immunity.
• To explore the potential of targeting the intersection of DDR and immune checkpoints in immunotherapy-refractory cancers.
• To evaluate Merkel cell carcinoma (MCC) as a model for testing these combined therapeutic strategies.

Main Methods:

• Review of preclinical studies on DDR inhibitors and their effects on anti-tumor immunity.
• Analysis of MCC's characteristics, including its immunogenicity, cell cycle checkpoint deficiencies, and sensitivity to DNA damage.
• Conceptual framework for targeting DDR and immune checkpoints in MCC.

Main Results:

• DDR inhibitors may promote immunogenic cell death, enhancing antigen presentation and adaptive immune responses.
• MCC exhibits high immunogenicity and susceptibility to DNA-damaging agents due to p53/Rb dysfunction and Myc upregulation.
• MCC's inherent radiosensitivity and immune responsiveness make it a suitable model for this research.

Conclusions:

• Targeting the interplay between DDR and immune checkpoints presents a novel strategy for overcoming immunotherapy resistance.
• MCC serves as an ideal platform to test the synergistic effects of DDR inhibition and immunotherapy.
• This approach holds potential for improving outcomes in patients with immunotherapy-refractory metastatic cancers.